Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

June 28, 2021 1:45 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
28 JUNE 2021 at 08.45 EEST
        

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 24 June 2021 above five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

 % of shares and voting rights
(total of point A)
% of shares and voting rights through financial instruments
(total of point B)
Total of both in % (points A + B)Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached5.00% shares

 

Below 5% voting rights
0.07% shares

 

Below 5% voting rights
5.07% shares

 

Below 5% voting rights
141,134,278 shares

 

806,883,011 voting rights
Position of previous notification (if applicable)4.94% shares

 

Below 5% voting rights
0.07% shares

 

Below 5% voting rights
5.01% shares

 

Below 5% voting rights
 

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares
ISIN code
Number of shares and voting rights% of shares and voting rights
 Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)
FI0009014377 7,065,217 shares

 

Below 5% voting rights
 5.00% shares

 

Below 5% voting rights
POINT A SUBTOTAL7,065,217 shares

 

Below 5% voting rights
5.00% shares

 

Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rights
Securities LentN/AN/APhysical66,597 shares

 

Below 5% voting rights
0.04% shares

 

Below 5% voting rights
CFDN/AN/ACash35,285 shares

 

Below 5% voting rights
0.02% shares

 

Below 5% voting rights
   POINT B SUBTOTAL101,882 shares

 

Below 5% voting rights
0.07% shares

 

Below 5% voting rights

Orion Corporation

Timo Lappalainen

President and CEO
   Olli Huotari

SVP, Corporate Functions
 

                                                
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

ORION CORPORATION

STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
28 JUNE 2021 at 08.40 EEST
        

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 24 June 2021 above five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

 % of shares and voting rights
(total of point A)
% of shares and voting rights through financial instruments
(total of point B)
Total of both in % (points A + B)Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached5.00% shares

 

Below 5% voting rights
0.07% shares

 

Below 5% voting rights
5.07% shares

 

Below 5% voting rights
141,134,278 shares

 

806,883,011 voting rights
Position of previous notification (if applicable)4.94% shares

 

Below 5% voting rights
0.07% shares

 

Below 5% voting rights
5.01% shares

 

Below 5% voting rights
 

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares
ISIN code
Number of shares and voting rights% of shares and voting rights
 Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)
FI0009014377 7,065,217 shares

 

Below 5% voting rights
 5.00% shares

 

Below 5% voting rights
POINT A SUBTOTAL7,065,217 shares

 

Below 5% voting rights
5.00% shares

 

Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rights
Securities LentN/AN/APhysical66,597 shares

 

Below 5% voting rights
0.04% shares

 

Below 5% voting rights
CFDN/AN/ACash35,285 shares

 

Below 5% voting rights
0.02% shares

 

Below 5% voting rights
   POINT B SUBTOTAL 

0.07% shares

 

Below 5% voting rights
 

Orion Corporation

Timo Lappalainen

President and CEO
   Olli Huotari

SVP, Corporate Functions
 

                                                
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.




Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Twitter